Biochemical assessment of metabolic associated fatty liver disease

Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guerra-Ruiz Armando R., Casals Gregori, Iruzubieta Paula, Lalana Marta, Leis Alba, López Rosa María, Crespo Javier, Morales-Ruiz Manuel
Formato:	article
Lenguaje:	EN ES
Publicado:	De Gruyter 2021
Materias:	hepatic steatosis liver fibrosis metabolic-associated fatty liver disease serum markers steatohepatitis Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/4e33d0f9576b45d187bf542aad328304
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e33d0f9576b45d187bf542aad328304
record_format	dspace
spelling	oai:doaj.org-article:4e33d0f9576b45d187bf542aad3283042021-12-05T14:10:39ZBiochemical assessment of metabolic associated fatty liver disease2628-491X10.1515/almed-2021-0009https://doaj.org/article/4e33d0f9576b45d187bf542aad3283042021-03-01T00:00:00Zhttps://doi.org/10.1515/almed-2021-0009https://doaj.org/toc/2628-491XMetabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.Guerra-Ruiz Armando R.Casals GregoriIruzubieta PaulaLalana MartaLeis AlbaLópez Rosa MaríaCrespo JavierMorales-Ruiz ManuelDe Gruyterarticlehepatic steatosisliver fibrosismetabolic-associated fatty liver diseaseserum markerssteatohepatitisMedical technologyR855-855.5ENESAdvances in Laboratory Medicine, Vol 2, Iss 2, Pp 199-208 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	hepatic steatosis liver fibrosis metabolic-associated fatty liver disease serum markers steatohepatitis Medical technology R855-855.5
spellingShingle	hepatic steatosis liver fibrosis metabolic-associated fatty liver disease serum markers steatohepatitis Medical technology R855-855.5 Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel Biochemical assessment of metabolic associated fatty liver disease
description	Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of the population is at risk of developing severe liver disease. The integration of non-invasive serological markers in the stratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.
format	article
author	Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel
author_facet	Guerra-Ruiz Armando R. Casals Gregori Iruzubieta Paula Lalana Marta Leis Alba López Rosa María Crespo Javier Morales-Ruiz Manuel
author_sort	Guerra-Ruiz Armando R.
title	Biochemical assessment of metabolic associated fatty liver disease
title_short	Biochemical assessment of metabolic associated fatty liver disease
title_full	Biochemical assessment of metabolic associated fatty liver disease
title_fullStr	Biochemical assessment of metabolic associated fatty liver disease
title_full_unstemmed	Biochemical assessment of metabolic associated fatty liver disease
title_sort	biochemical assessment of metabolic associated fatty liver disease
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/4e33d0f9576b45d187bf542aad328304
work_keys_str_mv	AT guerraruizarmandor biochemicalassessmentofmetabolicassociatedfattyliverdisease AT casalsgregori biochemicalassessmentofmetabolicassociatedfattyliverdisease AT iruzubietapaula biochemicalassessmentofmetabolicassociatedfattyliverdisease AT lalanamarta biochemicalassessmentofmetabolicassociatedfattyliverdisease AT leisalba biochemicalassessmentofmetabolicassociatedfattyliverdisease AT lopezrosamaria biochemicalassessmentofmetabolicassociatedfattyliverdisease AT crespojavier biochemicalassessmentofmetabolicassociatedfattyliverdisease AT moralesruizmanuel biochemicalassessmentofmetabolicassociatedfattyliverdisease
_version_	1718371839019843584

Biochemical assessment of metabolic associated fatty liver disease

Ejemplares similares